Yu Huang

Mr. Yu Huang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in Biomaterials
Verified
Journal Article
Closed access
YHYu Huang
Yu Huang
WHWeichao Hu
Weichao Hu
KXKaige Xu
Kaige Xu
RDRuijue Dan
Ruijue Dan
STShali Tan
Shali Tan
SYShiming Yang
Shiming Yang

23 December 2025 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
WYWang Ying
Wang Ying
CZChuanhao Zheng
Chuanhao Zheng
CGChunli Gong
Chunli Gong
JYJunxiao Yuan
Junxiao Yuan
GXGuoyang Xu
Guoyang Xu
QLQiang Luo
Qiang Luo

1 June 2025 in Bioactive Materials
Verified
Journal Article
Open access
SLSirui Li
Sirui Li
LZLan Zhou
Lan Zhou
YHYu Huang
Yu Huang
STShupei Tang
Shupei Tang
Acute kidney injury (AKI) remains a prevalent and critical clinical condition. Although considerable advancements have been achieved in clinical and fundamental research in recent decades, the enhancements in AKI diagnosis and therapeutic approaches, such as the development of emerging biomarkers including neutrophil gelatinase-associated lipocalin (NGAL) and liver fatty acid-binding protein (FABP1) for early detection of AKI and the exploration of "goal-directed" hemodynamic treatment methods and renal replacement therapies, have yet to fulfill the demands of modern medicine. Extracellular vesicles (EVs) serve as pivotal messengers in cell-to-cell communication, exerting a vital impact on both physiological and pathological processes. They exhibit immense potential as disease regulators, innovative biomarkers, therapeutic agents, and drug delivery vehicles. In recent times, the diagnostic and therapeutic potential of EVs in AKI has garnered widespread recognition and exploration, making them a focal point in clinical research. Consequently, a comprehensive overview of EVs' role in AKI is of great importance. This review delves into the multifaceted roles of EVs from diverse cellular sources, including tubular epithelial cells (TECs), mesenchymal stem cells (MSCs), progenitor cells, platelets and macrophages, within the context of AKI. It scrutinizes their contributions to disease progression and mitigation, their diagnostic marker potential, and encompasses a variety of conventional and novel EVs extraction techniques suitable for AKI clinical applications. Moreover, it underscores four innovative strategies for engineering EVs to boost production efficiency, targeting precision, circulatory stability and therapeutic potency. These advancements pave the way for novel approaches in the diagnosis and treatment of AKI. We are optimistic that as research into EVs progresses, the future will bring about earlier detection, more tailored treatments, and a more holistic management of AKI.

27 September 2021 in Nanomedicine
Verified
Journal Article
Closed access
ZYZhuo Yang
Zhuo Yang
ELEn Liu
En Liu
SWSu Min Wang
Su Min Wang
YXYu Feng Xiao
Yu Feng Xiao
SZShuo Zeng
Shuo Zeng
YHYu Huang
Yu Huang
Aim: Long noncoding RNA (lncRNA) BC032469-dependent gold nanoparticle molecular beacons (AuNP-MB) were constructed for the detection of gastric cancer cells. Materials & methods: The AuNP-MBs were ...

1 August 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MLMandi Luo
Mandi Luo
PTPeng Tang
Peng Tang
XCXichan Chen
Xichan Chen
WLWei-Hua Lan
Wei-Hua Lan
STShupei Tang
Shupei Tang
YHYu Huang
Yu Huang
Renal cell carcinoma (RCC) is a highly immunogenic malignancy, and immune checkpoint inhibitor-based regimens have substantially improved clinical outcomes. However, primary resistance, acquired resistance, interpatient heterogeneity, and treatment-related systemic toxicity continue to limit therapeutic efficacy. Immune evasion in RCC can be summarized into three interconnected levels: defective immune priming and checkpoint-mediated immunosuppression; vascular-metabolic barriers that impede immune-cell infiltration and effector function; and a suppressive immune microenvironment shaped by myeloid cells, regulatory lymphocytes, cytokines, and extracellular vesicles. Together, these barriers impair effector-cell function and promote T-cell exhaustion. Nanodelivery platforms provide new opportunities to overcome these multistage immunosuppressive constraints through programmable payload loading, spatiotemporally controlled local delivery, and material-enabled modulation of the tumor microenvironment. Based on this multilevel immune-evasion framework, this review organizes current evidence and systematically discusses representative intervention strategies, including restoration of antigen presentation and innate immune sensing, maintenance of effector-cell activation, remodeling of the vascular–metabolic microenvironment, and reprogramming of suppressive immune networks. We further compare the advantages and limitations of lipid-based, polymeric, and inorganic nanoplatforms in terms of payload compatibility, release control, intrinsic physicochemical activity, biosafety, manufacturability, and clinical translatability, and emphasize that therapeutic components should achieve mechanistically grounded synergy rather than simple combination. Although current studies have demonstrated therapeutic potential, RCC nano-immunotherapy remains largely at the preclinical stage and is constrained by limited model translatability, heterogeneous tumor delivery, uncertain long-term safety, manufacturing complexity, and the lack of standardized evaluation criteria. Future efforts should prioritize structurally simplified, mechanistically defined, tumor-microenvironment-responsive platforms, together with biomarker-guided patient stratification and standardized evaluation systems, to facilitate the translation of RCC nano-immunotherapy into reproducible treatment strategies with clear clinical benefit.